NCT07876518Not yet recruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity
AN INTERVENTIONAL PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ASCENDING DOSES OF PF-08656795 IN ADULTS WITH OVERWEIGHT OR OBESITY
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
This study will look at how different amounts of the study medicine, called PF-08656795, are tolerated and act in adults with overweight or obesity. Doctors will check if each person meets the study conditions, including age, body weight, and general health. People with certain medical conditions will not be able to take part in the study. The study is seeking participants who are: * adults, 18 to 70 years of age (inclusive) * have a body mass index (BMI) equal to, or more than 25 kilograms/meter square (kg/m2) up to 40 kg/m2. * limited mild, stable long-term medical conditions are allowed as assessed by the study doctor. People who want to join the study will first go through a screening period of up to 4 weeks. The study will look at how the study medicine is tolerated, including whether participants have any reactions. It will assess how they feel after receiving multiple doses. It will also measure the amounts of study medicine in the blood and urine over time. Participants will take part in this study for about 24 to 40 weeks including treatment and follow-up period after the final dose. Treatment duration may vary depending on their assigned group.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 9 Oct 2026
- Start date
- 30 Oct 2026
- Primary completion date
- 16 Nov 2028
- Lead sponsor
- Pfizer
- Diseases
- Obesity
- NCT number
- NCT07876518
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 150
- From 30 Oct 2026 to the primary completion date, 16 Nov 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Inclusion:
- Body mass index (BMI) ≥25 to ≤40 kg/m2; with stable body weight for ≥3 months prior to screening.
- Participants are generally otherwise healthy but may have mild chronic conditions (eg, dyslipidemia or hypertension)
- Exclusion:
- \- Individuals with clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurological, or allergic disease, are not eligible to participate.
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.